Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
50.74
87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Total Receivables
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Receivables
¥3.1B
|
CAGR 3-Years
62%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Receivables
¥3.2B
|
CAGR 3-Years
77%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Receivables
¥1.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Receivables
¥392.5m
|
CAGR 3-Years
58%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Receivables
¥25.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
41%
|
CAGR 10-Years
46%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Receivables
¥230.8m
|
CAGR 3-Years
72%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View
In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.
See Also
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Receivables?
Total Receivables
3.1B
CNY
Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Receivables amounts to 3.1B CNY.
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
72%
Over the last year, the Total Receivables growth was -23%. The average annual Total Receivables growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 62% over the past three years , 72% over the past five years .
You don't have any saved screeners yet
